Dabur ties up with Abbott's biotech arm for US cancer drug market foray

摘要

Dabur Pharma has tied up with the biotech arm of US drug major Abbott Laboratories to make a foray into the American market.Hospira,a 2-bn company,will start distributing Dabur's cancer drug 'carboplatin' in the 100-mn US market for the drug in a month,informed Dabur CEO,Mr.Ajay Vij.Dabur has already received the marketing approval.